Oculis Holding AG Ordinary shares OCS

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

• Zacks Investment Research 23 sept

  Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

  Halozyme Therapeutics shares rose 3.3% to $115.13 on strong volume, driven by investor optimism around its ENHANZE drug-delivery technology collaborations with major pharmaceutical companies. The company is expected to report quarterly earnings of $2.25 per share (+30.8% YoY) and revenues of $470.95 million (+32.9% YoY). With a 2.6% upward revision in consensus EPS estimates over the past 30 days and a Zacks Rank #2 (Buy) rating, analysts suggest monitoring the stock for potential continued strength.

  

• GlobeNewswire Inc. 11 jun

  Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

  Oculis Holding AG announced it will present Privosegtor, a novel neuroprotective therapy candidate, at Clinical Trials at the Summit 2026 on June 13, 2026. The presentation will highlight Privosegtor's development journey from discovery through the PIONEER registrational trials for optic neuritis treatment. The drug has received Breakthrough Therapy and PRIME designations and showed positive Phase 2 ACUITY trial results.

  

• GlobeNewswire Inc. 11 jun

  Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

  Oculis announced a presentation at Clinical Trials at the Summit 2026 on its investigational drug Privosegtor, a neuroprotective therapy candidate for optic neuritis. The company highlighted positive Phase 2 ACUITY trial results and regulatory milestones including FDA Breakthrough Therapy designation and EMA PRIME designation, as it advances the PIONEER registrational program.